Approval Year
Substance Class |
Protein
Created
by
admin
on
Edited
Sat Dec 16 12:03:23 UTC 2023
by
admin
on
Sat Dec 16 12:03:23 UTC 2023
|
Protein Sub Type | |
Sequence Origin | HUMAN |
Sequence Type | COMPLETE |
Record UNII |
TP3WG3U0B5
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
P48551
Created by
admin on Sat Dec 16 12:03:23 UTC 2023 , Edited by admin on Sat Dec 16 12:03:23 UTC 2023
|
PRIMARY | |||
|
TP3WG3U0B5
Created by
admin on Sat Dec 16 12:03:23 UTC 2023 , Edited by admin on Sat Dec 16 12:03:23 UTC 2023
|
PRIMARY |
From | To |
---|---|
1_13 | 1_96 |
1_59 | 1_67 |
1_181 | 1_201 |
Glycosylation Type | HUMAN |
Glycosylation Link Type | Site |
---|---|
N | 1_32 |
N | 1_61 |
N | 1_90 |
N | 1_162 |
N | 1_166 |
Related Record | Type | Details | ||
---|---|---|---|---|
|
AGONIST -> TARGET | |||
|
AGONIST -> TARGET |
Nova exhibited a higher binding affinity for IFN receptor 2 (IFNR2) than rhIFN-α2b, which is one of the
possible reasons accounting for its stronger actions against tumor cells compared with rhIFN-α2b.
AGONIST
Kd
|
||
|
ACTIVATOR -> TARGET | |||
|
AGONIST -> TARGET | |||
|
AGONIST -> TARGET |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
MOL_WEIGHT | CHEMICAL |
|